Cardinal Health Narrows FY23 Non-GAAP EPS Guidance - Quick Facts
RTTNews 2023-06-08 11:12:03 • 1 min
Cardinal Health (CAH) narrowed its fiscal 2023 guidance ranges for non-GAAP EPS and Pharmaceutical segment profit. The company now expects non-GAAP EPS in a range of $5.65 to $5.80, revised from $5.60 to $5.80. This corresponds to 13% growth at the mid-point, the company noted. Pharmaceutical segment profit is now projected 11% to 12% growth, from prior guidance range of 10.5% to 12% growth.
The company reiterated other fiscal 2023 guidance assumptions provided on May 4th, 2023.
For fiscal 2024, the company projects: non-GAAP EPS in a range of $6.45 to $6.70; and pharmaceutical segment profit in a range of 4% to 6% growth.
